BioAge Labs, Inc (BIOA)vsHaleon plc (HLN)
BIOA
BioAge Labs, Inc
$8.49
-1.85%
HEALTHCARE · Cap: $389.67M
HLN
Haleon plc
$9.19
-0.33%
HEALTHCARE · Cap: $44.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 107597% more annual revenue ($11.15B vs $10.36M). HLN leads profitability with a 14.5% profit margin vs 0.0%. HLN earns a higher WallStSmart Score of 51/100 (C-).
BIOA
Avoid30
out of 100
Grade: F
HLN
Buy51
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Areas to Watch
1.6% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : BIOA
The strongest argument for BIOA centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bear Case : BIOA
The primary concerns for BIOA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
HLN is growing revenue faster at 2.2% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HLN scores higher overall (51/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioAge Labs, Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various customers in the chemical market primarily in the United States and Canada. The company is headquartered in Montreal, Canada.
Visit Website →Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?